Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolastatin-10 in Hormone Refractory Prostate Cancer
NCT00003626Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Oct 1998
- Primary completion
- Dec 1999
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dolastatin 10 in prostate cancer (PCa), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Objective Response Rate. Started Oct 1998; status: completed.
02
Drugs
dolastatin 10
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003626.